在美国,每年新诊断的头颈部鳞状细胞癌(除外表层皮肤癌)的病例约为37000例。而且近几年来,头颈部癌5年存活期也几乎没有什么改变。为了增长存活期,对于新的治疗方法或现有方法的联合应用必须要予以应有的鉴定估计。体外培养的鳞状细胞癌克隆形成测定(Clongenic assay)对于阐述这些治疗方法应是一个有用的方法。尽管人类肿瘤细胞的双层琼脂干细胞测 In the United States, there are approximately 37,000 new cases of head and neck squamous cell carcinoma (excluding superficial skin cancer) diagnosed each year. In recent years, there has been almost no change in the 5-year survival of head and neck cancer. In order to increase survival, the combined application of new therapeutic methods or existing methods must be properly assessed. In vitro cultured squamous cell carcinoma cloning assays (Clongenic assays) should be a useful method for elucidating these treatments. Despite the double-layer agar stem cell assay of human tumor cells